

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/079,384	02/20/2002	Didier Communi	9409/2135	7524
29933	7590 02/23/2004		EXAMINER	
PALMER & DODGE, LLP		MURPHY, JOSEPH F		
	M. WILLIAMS GTON AVENUE		ART UNIT	PAPER NUMBER
BOSTON, MA 02199			1646	

DATE MAILED: 02/23/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/079.384	COMMUNI ET AL.				
Office Action Summary	Examiner	Art Unit				
·	Joseph F Murphy	1646				
The MAILING DATE of this communication app	<u> </u>					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 20 February 2002.						
2a) ☐ This action is FINAL . 2b) ☑ This	This action is FINAL . 2b)⊠ This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
 4) Claim(s) 1-54 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 						
 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) <u>1-54</u> are subject to restriction and/or example. 	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priorical application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage				
1440.chm.o.n4/o.)						
Attachment(s) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)				
Provides of References Cited (1 TO-692) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da	•				

Application/Control Number: 10/079,384

Art Unit: 1646

DETAILED ACTION

Page 2

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I-XIV. Claims 1-2, drawn to a GPCR polypeptide with the amino acid sequence selected from ONE of the following: SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28, classified in class 435, subclass 350.
- XV-XXVIII.Claims 3-7, drawn to an isolated polynucleotide encoding a GPCR with the polynucleotide sequence selected from ONE of the following: SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27, classified in class 435, subclass 69.1.
- XXIX-XXXXII.Claims 8-9, drawn to a transgenic non-human animal comprising ONE of the following polynucleotides: SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27, classified in class 800, subclass 8.
- XXXXIII.Claims 10-26, 40 drawn to a method of identifying an agent which modulates GPCRx11 with the amino acid sequence of SEQ ID NO: 12 (see Specification at 3, lines 1-3), classified in class 435, subclass 7.2.
- XXXXIV-LVI.Claims 27-39, drawn to a method of identifying an agent which modulates ONE of the following: SEQ ID NO: 2, 4, 6, 8, 10, 14, 16, 18, 20, 22, 24, 26 and 28, classified in class 435, subclass 7.2.
- LVII. Claim 41, drawn to a method of diagnosing a disease by amplifying a polynucleotide encoding GPCRx11 with the sequence SEQ ID NO: 12, classified in class 435, subclass 6.

Application/Control Number: 10/079,384

Art Unit: 1646

LVIII. Claims 42-54, drawn to a kit comprising a polypeptide of SEQ ID NO: 12 (GPCRx11) and angiopeptin, classified in class 530, subclass 350.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-XXXXII and LVIII are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function, and each has an independent use, that is distinct for each invention which cannot be exchanged. Nucleic acids, proteins and transgenic animals are distinct because their structures and modes of action are different, which require non-coextensive searches.

The nucleic acids of Inventions XV-XXVIII are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function, and each has an independent use, that is distinct for each invention which cannot be exchanged. In the instant case the nucleic acids have characteristic differences in their structure, as evidenced by the differing nucleic acid sequences.

The proteins of Inventions I-XIV are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function, and each has an independent use, that is distinct for each invention which cannot be exchanged. In the instant case the proteins have characteristic differences in their structure, as evidenced by the differing amino acid sequences.

The kit compositions of Invention LVIII are independent and distinct, from the protein claims of Inventions I-XIV, each from the other, because they are products which possess characteristic differences in structure and function, and each has an independent use, that is distinct for each invention which cannot be exchanged. In the instant case the kit composition

Application/Control Number: 10/079,384

Art Unit: 1646

comprises angiopeptin, thus the kit composition has a characteristic difference in the structure as compared to the proteins of Inventions I-XIV.

Inventions XXXXIII- LVII are independent and distinct, each from the other, because the methods are practiced with materially different starting materials, have materially different process steps, and are for materially different purposes. The methods of Inventions XXXXIII-LVI require the use of polypeptides which have differing amino acid sequences, thus the starting materials are different and are for different purposes since the polypeptides are different. The method of Invention LVII does not require the use of a polypeptide, but is a method of hybridization, and thus is independent and distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found

Page 5

Art Unit: 1646

allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Murphy whose telephone number is (571) 272-0877. The examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (571) 272-0871.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Joseph F. Murphy, Ph. D.

Patent Examiner Art Unit 1646

February 20, 2004